Factor VII, human

Antibody	Host	Catalogue No.	Size	Product Insert
Purified IgG	Sheep	SAFVII-IG	10 mg
Affinity purified IgG	Sheep	SAFVII-AP	0.5 mg
Peroxidase conjugated IgG	Sheep	SAFVII-HRP	0.2 mg
Affinity purified, FITC conjugated IgG	Sheep	SAFVII-APFTC	0.1 mg
Affinity purified, biotinylated IgG	Sheep	SAFVII-APBIO	0.1 mg
Matched Pair Antibodies for EIA		FVII-EIA	5 plates
Analyte Specific Reagents
– Affinity purified IgG		SAFVII-AP-ASR	0.5 mg
– Peroxidase conjugated IgG		SAFVII-HRP-ASR	0.2 mg

  SAFVII-APFTC – Flow Cytometry application

Description of Factor VII

Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 μg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and a 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate F.X and F.IX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin^1-3. References and Reviews 1. Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985. 2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993. 3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994. Related Products

SAFVII-AP Sheep anti-human FVII, affinity purified IgG

SAFVII-HRP Sheep anti-human FVII, IgG-peroxidase

FVII-EIA Paired antibody set for ELISA of FVII, 5 x 96 wells

FVII-DP Human plasma deficient in Factor VII, immune depleted

INH7-DP Factor VII Inhibitor Plasma, Frozen

INH7-LDP Factor VII Inhibitor Plasma, Lyophilized